信達生物(01801.HK):2020年達伯舒®(信迪利單抗注射液)銷售收入超22億元
格隆匯 1 月 29日丨信達生物(01801.HK)公吿,達伯舒®(信迪利單抗注射液)是由集團與禮來製藥共同開發、並於2019年3月成功推出。於2020年第四季度,達伯舒®(信迪利單抗注射液)有關銷售收入超過人民幣7億元。於2020年全年,達伯舒®(信迪利單抗注射液)有關銷售收入超過人民幣22億元。
公司欣然看到公司的主導產品達伯舒®(信迪利單抗注射液)自上市以來,收入保持逐季連續增長態勢,且作為首個進入國家醫保目錄的PD-1抑制劑,達伯舒®(信迪利單抗注射液)2020年收入實現同比大幅增長。公司相信其令人鼓舞的業績表明達伯舒®(信迪利單抗注射液)在中國的強大市場潛力以及公司作為高品質廠商的商業化能力。公司將繼續致力開發、製造並商業化老百姓用得起的高品質生物藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.